This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Abiomed Announces First Patient Supported With Impella CVAD

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of break-through heart support technologies, today announced the successful first human use of the Impella cVAD TM device, a new, percutaneous Impella heart pump that provides peak flow of approximately 4 liters of blood per minute. The Impella cVAD is designed to provide temporary circulatory support and reduce the workload of the heart muscle via a minimally invasive, catheter-based pump that is inserted percutaneously in the cardiac catheterization lab, without the need for surgical intervention.

The Impella cVAD further enhances Abiomed’s product portfolio, providing cardiologists with the clinical flexibility to offer increased flow for patients requiring more hemodynamic support. The increased flow is delivered on the same console platform, 9 French catheter, and introducer as the Impella 2.5.

An 85-year-old patient with complex coronary artery disease, compromised left heart function (ejection fraction of 20%), and prior myocardial infarction was percutaneously implanted with the Impella cVAD. The device generated an average blood flow of 3.5 liters and peak blood flow of approximately 4 liters per minute. Post procedure, the patient reported relief of angina; the Impella was explanted after 25 hours of support and the patient is currently awaiting discharge.

For the first-in-man experience, the Impella cVAD was implanted at the McGill University Health Centre (MUHC) in Montreal, Quebec by Dr. Giuseppe Martucci, Co-Director of the Adult Intervention Congenital and Structural Health Disease Laboratory at the MUHC. Dr. Martucci was accompanied by Dr. Renzo Cecere, Dr. Luc Bilodeau, and Dr. Nicolo Piazza.

“The Impella cVAD gave my patient a very high level of hemodynamic support, allowing me to conduct extensive revascularization and treat his triple-vessel coronary artery disease in one procedure — all while avoiding the accompanying risk of complications,” said Dr. Martucci. “This is another example of how the MUHC has made a safe, innovative, and minimally invasive procedure accessible to our patients. The device’s excellent blood flow gave us great flexibility and support and will allow the MUHC now to treat coronary artery disease patients who previously had limited treatment options and were unable to undergo traditional open-heart surgery,” added Dr. Cecere.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs